HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Aminopurine Compounds having the following structure: (I) wherein R1 , R2 and and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmu...

Full description

Saved in:
Bibliographic Details
Main Authors AYALA, LETICIA, KOIS, ADAM, CLAREEN, STEVEN S, NADOLNY, LISA, HUGHES, KEVIN, PLANTEVIN-KRENITSKY, VERONIQUE, MCCARRICK, MEG, SATOH, YOSHITAKA, SAHASRABUDHE, KIRAN, ALBERS, RONALD, SAPIENZA, JOHN, SLOSS, MARIANNE, SUDBECK, ELISE, HENDERSON, IAN, HILGRAF, ROBERT, DELGADO MEDEROS, MARIA M, COLE, ANDREW G, HEGDE, SAYEE, PALANKI, MOORTHY, WRIGHT, JONATHAN
Format Patent
LanguageEnglish
French
Published 03.09.2013
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Provided herein are Aminopurine Compounds having the following structure: (I) wherein R1 , R2 and and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof. L'invention porte sur des composés d'aminopurine de formule (I) dans laquelle: R1, R2 et R3 sont tels que définis dans la description et pouvant traiter ou prévenir, le cancer, les maladies cardio-vasculaires, les maladies rénales, les états auto-immunes, les états inflammatoires, la dégénérescence maculaire, l'ischemie-reperfusion, la douleur et les syndromes associés, l'amaigrissement morbide, troubles liés à l'amiante, l'hypertension pulmonaire et les syndromes associés, ou tout état pouvant être traité ou prévenu par inhibition du mécanisme de la voie JNK, le traitement ou la prévention se faisant par administration d'une dose efficace d'un composé d'aminopurine à un patient le nécessitant.
Bibliography:Application Number: CA20062595182